Lenvima

• 

Current role of mTOR inhibitors in metastatic kidney cancer

By Sharon Kell|2019-01-04T09:01:44+00:004 Jan 2019|Drug treatments|

The following video interview with Dr Eric Jonasch, from the [...]

Read More

Comments Off on Current role of mTOR inhibitors in metastatic kidney cancer

• 

Advances in kidney cancer drug treatments shake up drug choices

By Sharon Kell|2017-04-10T12:54:57+00:0010 Apr 2017|Drug treatments|

The following article provides a comprehensive summary of the changing [...]

Read More

Comments Off on Advances in kidney cancer drug treatments shake up drug choices

Combination therapy is promising for kidney cancer

By Sharon Kell|2017-01-23T09:40:46+00:0023 Jan 2017|Drug treatments|

In recent years, drugs that target the vascular endothelial growth [...]

Read More

Comments Off on Combination therapy is promising for kidney cancer

• 

Eisai has started phase III clinical trial with lenvatinib as a potential first-line treatment for advanced kidney cancer

By Sharon Kell|2016-10-05T11:08:53+00:005 Oct 2016|Drug treatments|

This week saw the initiation of a global phase III [...]

Read More

Comments Off on Eisai has started phase III clinical trial with lenvatinib as a potential first-line treatment for advanced kidney cancer

European Commission approves Kisplyx (lenvatinib) for advanced kidney cancer

By Sharon Kell|2016-09-16T19:33:27+00:0016 Sep 2016|Drug treatments|

The European Commission has approved Kisplyx (lenvatinib) for the treatment [...]

Read More

Comments Off on European Commission approves Kisplyx (lenvatinib) for advanced kidney cancer

Cabozantinib and lenvatinib recommended for approval by the EMA

By Sharon Kell|2016-07-26T15:55:51+00:0026 Jul 2016|Drug treatments|

Cabozantinib (Cabometyx, Ipsen Pharma) and lenvatinib (Kisplyx, Eisai Europe Ltd) [...]

Read More

Comments Off on Cabozantinib and lenvatinib recommended for approval by the EMA

• 

Lenvatinib plus everolimus improves progression-free survival in renal cell carcinoma

By Sharon Kell|2016-06-14T16:19:45+00:0014 Jun 2016|Drug treatments|

Data presented at the American Society of Clinical Oncology (ASCO) annual [...]

Read More

Comments Off on Lenvatinib plus everolimus improves progression-free survival in renal cell carcinoma

• 

FDA approves lenvatinib/everolimus combination for kidney cancer

By Sharon Kell|2016-05-16T12:09:46+00:0016 May 2016|Drug treatments|

The FDA has approved the combination of lenvatinib (Lenvima) and [...]

Read More

Comments Off on FDA approves lenvatinib/everolimus combination for kidney cancer